Aprepitant Injectable Emulsion
Name: Aprepitant Injectable Emulsion
CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of:
- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
Limitations Of Use
- CINVANTI has not been studied for the treatment of established nausea and vomiting.
Included as part of the "PRECAUTIONS" Section
There is no specific information on the treatment of overdosage with aprepitant.
In the event of overdose, CINVANTI should be discontinued and general supportive treatment and monitoring should be provided. Because of the antiemetic activity of CINVANTI, drug-induced emesis may not be effective in cases of CINVANTI overdosage.
Aprepitant is not removed by hemodialysis.